



(12) Translation of
European patent specification

(11) NO/EP 4160212 B1

NORWAY

(19) NO
(51) Int Cl.
G01N 33/574 (2006.01)
A61K 39/00 (2006.01)
C07K 16/28 (2006.01)
C07K 16/30 (2006.01)
C12N 5/00 (2006.01)
C12N 5/09 (2010.01)
C12Q 1/68 (2018.01)
G01N 33/50 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.06.10
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.04.17
(86)	European Application Nr.	22191296.7
(86)	European Filing Date	2009.01.13
(87)	The European Application's Publication Date	2023.04.05
(30)	Priority	2008.01.15, US, 11324 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
(73)	Proprietor	The Board of Trustees of the Leland Stanford Junior University, Office of the General Counsel Building 170, Third Floor, Main Quad P.O. Box 20386, Stanford, CA 94305-2038, USA
(72)	Inventor	WEISSMAN, Irving, L, Redwood City, 94061, USA MAJETI, Ravindra, Stanford, 94304, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54) Title **MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS**

(56) References
Cited:

EP-A1- 2 111 869
US-A1- 2004 213 792
Per-Arne Oldenborg et al: "Cd47-Signal Regulatory Protein (Sirpa) Regulates Fc-gamma and Complement Receptor-Mediated Phagocytosis", The Journal of Experimental Medicine, vol.193, no. 7, 2 April 2001 (2001-04-02), pages 855-861, XP055283803, Retrieved from the Internet: URL:<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193364/pdf/010027.pdf> [retrieved on 2016-06-27] JAISWAL SIDDHARTHA ET AL: "CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis", CELL, CELL PRESS, US, vol. 138, no. 2, 1 July 2009 (2009-07-01), pages 271-285, XP009160236, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2009.05.046 RAVINDRA MAJETI ET AL: "CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells", CELL, vol. 138, no. 2, 1 July 2009 (2009-07-01), pages 286-299, XP055277135, US ISSN: 0092-8674, DOI:

10.1016/j.cell.2009.05.045

M. JAN ET AL: "Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 12, 7 March 2011 (2011-03-07), pages 5009-5014, XP055029836, ISSN: 0027-8424, DOI: 10.1073/pnas.1100551108

JAMIESON C ET AL: "Increased expression of CD47 is a constant marker in mouse and human myeloid leukemias", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 106, 1 January 2005 (2005-01-01), page 911A, XP008138745, ISSN: 0006-4971

GARDAI S J ET AL: "Cell-surface calreticulin initiates clearance of viable apoptotic cells through trans-activation of LRP on the phagocyte", CELL, ELSEVIER, AMSTERDAM NL, vol. 123, 21 October 2005 (2005-10-21), pages 321-334, XP002432361, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2005.08.032

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

4160212

1

5 **Patentkrav**

1. Monoklonalt antistoff rettet mot CD47, som blokkerer interaksjonen av CD47 med SIRP α , for anvendelse innen behandlingen av en pre-leukemisk tilstand ved å hemme engraftment av AML LSCs (leukemiske stamceller), hvori blokkering av interaksjonen av CD47 med SIRP α stimulerer fagocytose av AML LSCs gjennom makrofager.

2. Det monoklonale antistoffet for anvendelse ifølge krav 1, hvori den pre-leukemiske tilstanden er et myelodysplastisk syndrom (MDS) eller en myeloproliferativ lidelse (MPD).

15